Prognosis in hormon receptor negative breast cancer patients according to ERBB2 status

Neoplasma

Volumn 55, Issue 6, 2008, Pages 544-548

  Dogan, L ^a   Atalay, C ^a   Yilmaz, K B ^a   Ozaslan, C ^a  

^a ANKARA ONCOLOGY HOSPITAL   (Turkey)

Author keywords

Breast cancer; Hormon receptor negative; Survival; Triple negative

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROGNOSIS; TUMOR VOLUME; ADULT; AGED; BREAST TUMOR; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; NEOPLASM; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 59749093999     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. PEROU CM, SORLIE T, EISEN MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
2. SORLIE T, PEROU CM, TIBSHIRANI R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
3. SORLIE T, TIBSHIRANI R, PARKER J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423.
4. CAREY LA, PEROU CM, LIVASY CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502. (Pubitemid 43854964)
5. BAUER KR, BROWN M, CRESS RD et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer 2007; 109: 1721-1728.
6. RAKHA EA, EL-SAYED ME, GREEN AR et al. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25-32. (Pubitemid 46120191)
7. GREENE FL, PAGE DL, FLEMING ID et al. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002.
8. TURNER NC, REIS-FILHO JS, RUSSELL AM et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007; 26: 2126-2132. (Pubitemid 46514749)
9. ABD EL-REHIM DM, BALL G, PINDER SE et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analysis. Int J Cancer 2005; 116: 340-350.
10. van de RIJN M, PEROU CM, TIBSHIRANI R et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002; 161: 1991-1996.
11. SOTIRIOU C, NEO SY, MCSHANE LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100: 10393-10398.
12. CLEATOR S, HELLER W, COOMBES RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007; 8: 235-244. (Pubitemid 46291713)
13. ROUZIER R, PEROU CM, SYMMANS WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685. (Pubitemid 41170290)
14. CAREY LA, DEES EC, SAWYER LR et al. The triple negative paradox: primary tumor chemosensitivity of the basal-like breast cancer phenotype. Clin Cancer Res 2007; 13: 2329-2334.